Business Context and Reporting Period
Company: Gyre Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2026
Reporting Period: Single event date (May 12, 2026)
The filing discloses a material regulatory milestone for the Company's lead product candidate, F351 (Hydronidone), intended for the treatment of chronic hepatitis B-induced liver fibrosis.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Milestone: On May 12, 2026, Gyre Pharmaceuticals Co., Ltd., the Company's majority indirectly owned subsidiary, received notification of acceptance of its New Drug Application (NDA) from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA). This acceptance pertains to F351 (Hydronidone).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the NDA acceptance but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this 8-K text.
Unusual Items: None reported beyond the standard regulatory filing of the NDA acceptance.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the NDA acceptance timeline and next steps.
- Confirm the regulatory status of F351 (Hydronidone) with the China National Medical Products Administration.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K contains no financial data.
- Assess the potential commercial impact of an NDA acceptance in China versus other global markets.